Medpace Inc.
MEDP | NASDAQ
$624.20
+$11.87 (+1.94%)
At close: Sep 21, 2026, 4:00 PM ET
$624.20
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Key Executives
| Name | Position |
|---|---|
| August James Troendle | CEO, President & Chairman |
| Kevin Brady | Chief Financial Officer & Treasurer |
| Brad W. Hansman | Executive Vice President of Operations |
| Gina Leisring | Senior Vice President of Clinical Monitoring |
| John T. Wynne | Chief Business Officer |
| Lauren Morris | Associate Director of Investors Relations |
| Reinilde Heyrman | Chief Medical Officer of Medical Department |
| Stephen Ewald | Chief Compliance Officer, General Counsel & Corporate Secretary |
| Todd Meyers | Vice President of Business Development & Marketing |
| Weimin Gai | Senior Vice President of Biometrics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 31, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 27, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Medpace Inc.
| Country | United States |
| IPO Date | Aug 10, 2016 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 6,500 |
| CEO | August James Troendle |
Contact Details
5375 Medpace Way Cincinnati,
Ohio 45227 United States
Stock Details
| Ticker Symbol | MEDP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001668397 |
| CUSIP Number | 58506Q109 |
| ISIN Number | US58506Q1094 |
| SIC Code | 8731 |
Recent News
- 11 hours ago / zacks.comMedpace (MEDP) Outperforms Broader Market: What You Need to Know
- 7 days ago / zacks.comMedpace (MEDP) Ascends While Market Falls: Some Facts to Note
- 21 days ago / zacks.comWhy Medpace (MEDP) is a Top Growth Stock for the Long-Term
- 27 days ago / investors.comMedpace Stock Hovers Near Entry, Offers Second Chance After July Spike
- 27 days ago / fool.comWhat Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock
- 1 month ago / zacks.comWhy Is Medpace (MEDP) Up 1.1% Since Last Earnings Report?
- 1 month ago / zacks.comMedpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
- 1 month ago / zacks.comHere's Why Medpace (MEDP) is a Strong Growth Stock
- 1 month ago / prnewswire.comKuehn Law Encourages Investors of Medpace Holdings, Inc. to Contact Law Firm
- 2 months ago / zacks.comMedpace (MEDP) Just Flashed Golden Cross Signal: Do You Buy?
Add to Watchlist
Select watchlists to add or remove MEDP